Allspring Global Investments Holdings LLC Has $31.96 Million Holdings in Perrigo Company plc $PRGO

Allspring Global Investments Holdings LLC lifted its holdings in Perrigo Company plc (NYSE:PRGO) by 2.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,165,240 shares of the company’s stock after purchasing an additional 22,833 shares during the period. Allspring Global Investments Holdings LLC owned 0.85% of Perrigo worth $31,963,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of PRGO. GAMMA Investing LLC lifted its stake in shares of Perrigo by 91.9% in the 1st quarter. GAMMA Investing LLC now owns 3,685 shares of the company’s stock valued at $103,000 after purchasing an additional 1,765 shares during the last quarter. Fifth Third Bancorp lifted its position in Perrigo by 62.0% during the 1st quarter. Fifth Third Bancorp now owns 2,218 shares of the company’s stock worth $62,000 after acquiring an additional 849 shares during the last quarter. State of Alaska Department of Revenue lifted its position in Perrigo by 2.8% during the 1st quarter. State of Alaska Department of Revenue now owns 15,984 shares of the company’s stock worth $448,000 after acquiring an additional 430 shares during the last quarter. Blue Trust Inc. lifted its position in Perrigo by 110.4% during the 1st quarter. Blue Trust Inc. now owns 2,619 shares of the company’s stock worth $73,000 after acquiring an additional 1,374 shares during the last quarter. Finally, Lecap Asset Management Ltd. acquired a new position in Perrigo during the 1st quarter worth $724,000. Institutional investors and hedge funds own 95.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PRGO. JPMorgan Chase & Co. cut their target price on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Perrigo in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Sunday, September 28th. Finally, Canaccord Genuity Group cut their target price on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $34.00.

Insider Buying and Selling at Perrigo

In other Perrigo news, Director Geoffrey M. Parker bought 4,375 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were acquired at an average price of $22.97 per share, with a total value of $100,493.75. Following the completion of the purchase, the director directly owned 33,287 shares in the company, valued at $764,602.39. The trade was a 15.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Eduardo Guarita Bezerra bought 3,000 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was acquired at an average cost of $22.74 per share, for a total transaction of $68,220.00. Following the purchase, the chief financial officer owned 48,949 shares of the company’s stock, valued at $1,113,100.26. This trade represents a 6.53% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 10,118 shares of company stock worth $232,699. Insiders own 0.70% of the company’s stock.

Perrigo Stock Performance

NYSE:PRGO opened at $21.38 on Thursday. The firm’s 50-day moving average is $22.43 and its 200-day moving average is $25.08. Perrigo Company plc has a 52-week low of $20.51 and a 52-week high of $30.93. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.24 and a current ratio of 2.32. The company has a market cap of $2.94 billion, a price-to-earnings ratio of -36.86 and a beta of 0.43.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.02). The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The business’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.53 EPS. Equities research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 29th were paid a $0.29 dividend. The ex-dividend date of this dividend was Friday, August 29th. This represents a $1.16 dividend on an annualized basis and a yield of 5.4%. Perrigo’s payout ratio is presently -200.00%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.